In This Article:
The United States market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 23.83% | 24.32% | ★★★★★★ |
| Ardelyx | 25.24% | 69.64% | ★★★★★★ |
| Sarepta Therapeutics | 24.00% | 42.51% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.35% | 70.33% | ★★★★★★ |
| Clene | 78.50% | 60.16% | ★★★★★★ |
| TG Therapeutics | 34.66% | 56.98% | ★★★★★★ |
| Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
| Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 246 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
CareDx
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CareDx, Inc. focuses on developing and commercializing diagnostic solutions for transplant patients and caregivers globally, with a market cap of approximately $1.32 billion.
Operations: The company generates revenue primarily from its biotechnology segment, amounting to $312.78 million.
CareDx has showcased resilience and strategic foresight in the high-growth tech landscape, particularly with its recent advancements in HLA genotyping technologies. The company's revenue surged to $82.88 million in Q3 2024, up from $67.19 million the previous year, indicating a robust growth trajectory of 12.3% annually. This performance is bolstered by strategic alliances like the one with Dovetail Genomics, aiming to revolutionize organ transplant matching through next-gen sequencing solutions. Furthermore, CareDx's commitment to R&D is evident as they integrate AI enhancements into their offerings, aligning with industry shifts towards more data-driven and personalized medical solutions. These efforts are set against a backdrop of improved financial health, with a significant reduction in net loss to $7.41 million from $23.49 million year-over-year and an optimistic revenue forecast increase for 2024, setting a promising stage for future growth.
-
Click to explore a detailed breakdown of our findings in CareDx's health report.
-
Gain insights into CareDx's past trends and performance with our Past report.
Amicus Therapeutics
Simply Wall St Growth Rating: ★★★★★☆
Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to discovering, developing, and delivering medicines for rare diseases with a market capitalization of approximately $2.98 billion.